Colorado 2023 Regular Session

Colorado Senate Bill SB144

Introduced
2/8/23  
Refer
2/8/23  
Report Pass
3/2/23  
Refer
3/2/23  
Engrossed
3/11/23  
Refer
3/11/23  
Report Pass
3/28/23  
Refer
3/28/23  
Enrolled
4/17/23  
Engrossed
4/26/23  
Engrossed
4/27/23  
Enrolled
4/27/23  

Caption

Prescription Drugs For Chronic Pain

Impact

The bill's implementation could significantly affect how chronic pain patients are treated, allowing them to receive necessary medications without the fear of disciplinary repercussions for their prescribing doctors. Furthermore, SB144 ensures that healthcare providers are not pressured to adhere strictly to predetermined dosage limits but may operate based on their professional judgment and the unique needs of each patient. This modification aims to improve patient care by prioritizing personalized treatment plans over one-size-fits-all regulations.

Summary

SB144 addresses the prescription of controlled substances, specifically for patients suffering from chronic pain. The bill establishes guidelines on the responsibilities and rights of healthcare providers when prescribing medications classified under schedules II to V. It safeguards healthcare providers from disciplinary action if they prescribe, dispense, or administer these controlled substances in good faith and according to established medical practices aimed at alleviating chronic pain. SB144 emphasizes the importance of individualized patient assessments before any changes to medication dosages, allowing for a more tailored approach to pain management.

Sentiment

The sentiment surrounding SB144 has generally been supportive among healthcare providers who see it as a critical step towards enabling them to adequately support patients with chronic pain. However, there are concerns from some advocacy groups about potential misuse or over-prescription of opioids, leading to greater scrutiny around the management of chronic pain and ensuring that measures are in place to prevent drug diversion. As a result, the discourse reflects a cautious optimism balancing patient needs with public health considerations.

Contention

While the bill is seen as a progressive move towards improving patient care, there are contentious points regarding its potential implications for opioid regulations and patient safety. Critics worry that the lack of strict limits could lead to an increase in opioid prescriptions, thereby exacerbating the ongoing issues related to opioid dependency and abuse. The discussions have highlighted the fine line lawmakers must navigate between providing adequate support for pain sufferers and ensuring public safety against the backdrop of a nationwide opioid crisis.

Companion Bills

No companion bills found.

Similar Bills

NJ A2260

Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.

NJ A3630

Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.

CA AB845

Cannabidiol.

CT SB00511

An Act Concerning Opioids.

NJ A3342

Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven day supply, except in certain circumstances.

CT HB07395

An Act Concerning Opioid Abuse And Treatment.

CA AB2741

Prescription drugs: opioid medications: minors.

NJ A2191

Increases amount allowed in initial prescription for opioid drugs in cases of acute pain.